Merck’s efforts to combine its PD-1 blockbuster Keytruda with an experimental LAG-3 inhibitor hit a stumbling block Wednesday morning.
The company said a Phase 3 …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
SAN FRANCISCO — The Pascal device remained noninferior to MitraClip for prohibitive surgical risk patients with significant symptomatic degenerative mitral regurgitation (DMR) in full results
This is Part 7 of Embedded Bias, a series revealing how race-based clinical algorithms pervade medicine and why it’s so difficult to change them. PROVIDENCE,